TESARO (NASDAQ:TSRO) : The total negative money flow of $6.61 million on Wednesday indicates selling on strength. The inflow of money on upticks was $226.95 million, compared to $233.56 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.97. The negative money flow of $12.02 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $26.51 million in a block trade.The transaction value of block trade on downtick was $38.53 million. The uptick to downtick ratio was 0.69. The price action in the TESARO (NASDAQ:TSRO) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $78.33 with a gain of $41.12 , a change of 110.51% over the previous days close. The stock registered 81.24% for the week.
In an insider trading activity, The officer (VP of Finance & Administration), of Tesaro, Inc., English Edward C had unloaded 7,000 shares at $41.21 per share in a transaction on June 10, 2016. The total value of transaction was $288,470. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 40.5% of TESARO shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of 8.02%.
The company shares have dropped -34.42% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $66.95 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $43.24 and the 200 Day Moving Average price is recorded at $42.66. TESARO (NASDAQ:TSRO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $68.78 and $68.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $77.40, notching a gain of 108.01% for the day. The total traded volume was 19,094,609 . The stock had closed at $37.21 on the previous day.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.